CompletedPhase 1MDMA
Influence of Bupropion on the Effects of MDMA
Sponsored by University Hospital, Basel, Switzerland
NCT ID
NCT01771874
Target Enrollment
16 participants
Start Date
2013-01
Est. Completion
2013-09
About This Study
The purpose of this study is to determinate the effect of a pre-treatment with bupropion, a dopamine and norepinephrine transporter inhibitor, on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The study will provide further understanding of the dopaminergic regulation of mood.
Conditions Studied
Interventions
- •MDMA
- •Bupropion
- •Placebo
Eligibility
Age:18 Years - 45 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Age between 18 and 45 * Understanding of the German language * Subjects understand the procedures and the risks associated with the study * Participants must be willing to adhere to the protocol and sign the consent form * Participants must be willing to adhere to the protocol and sign the consent form * Participants must be willing to drink only alcohol-free liquids and no xanthine-containing products(such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day * Participants must be willing not to drive a traffic vehicle within 48 h following MDMA administration * Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session * Body mass index: 18-27 kg/m2 Exclusion Criteria: * Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>140/90 mmHg) or Hypotension (SBP\<85 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder * Current or previous psychotic or major affective disorder * Psychotic or major affective disorder in first-degree relatives * Prior illicit drug use (except tetrahydrocannabinol (THC)-containing products) more than 5 times or any time within the previous 2 months * Pregnant or nursing women * Participation in another clinical trial (currently or within the last 30 days) * Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.) * Tobacco smoking
Study Locations (1)
University Hospital Basel
Basel, Canton of Basel-City, Switzerland